Oxeladin

This article needs additional citations for verification. Please help improve this article by adding citations to reliable sources. Unsourced material may be challenged and removed. Find sources: "Oxeladin" – news · newspapers · books · scholar · JSTOR (July 2011) (Learn how and when to remove this message)

Oxeladin

Clinical data
AHFS/Drugs.com	International Drug Names
ATC code	R05DB09 (WHO)
Identifiers
IUPAC name 2-(2-diethylaminoethoxy)ethyl 2-ethyl-2-phenyl-butanoate
JSmol)	Interactive image
SMILES O=C(OCCOCCN(CC)CC)C(c1ccccc1)(CC)CC
InChI InChI=1S/C20H33NO3/c1-5-20(6-2,18-12-10-9-11-13-18)19(22)24-17-16-23-15-14-21(7-3)8-4/h9-13H,5-8,14-17H2,1-4H3 Y Key:IQADUMSPOQKAAO-UHFFFAOYSA-N Y
NY (what is this?)  (verify)

Oxeladin is a

centre of cough.

Oxeladin is indicated in all types of cough. Besides its

secretion.

• Irritative cough
• Allergic cough
• Psychogenic cough
• Treatment of cough in patients with heart disease (it has no action upon the
  cardiovascular system
  )
• Infectious cough: tracheitis, bronchitis, pneumonia
• Treatment of cough in pre- and post-operative treatment for bronchoscopy

Although

therapy.

Rarely, some patients have reported

. These usually disappear on reducing the dosage or interrupting the treatment.

Oxeladin differs from common antitussives that cause addiction (such as etilmorphin, codeine or its derivatives) in that there is no evidence of risk of addiction or dependence.

Oxeladin is available as drops, syrup and tablets, providing easier ways of management which will be chosen depending on the age and clinical stage.

Each 1ml (33 drops) contains oxeladin citrate 20 mg. The bottle contains 20ml of solution.

Each 100ml contains oxeladin citrate 200 mg. The bottle contains 100ml of syrup.

Each tablet contains oxeladin citrate 20 mg. The box contains 20 tablets in blister packs

• Children 2-5yrs: 2.5ml-5ml (17 drops) every 4–6 hours
• Children 6-12 yrs: 10ml (33 drops), or 1 tablet, every 4–6 hours
• Children 12 yrs and over and adults: 15ml (50 drops), or 2 tablets, every 4–6 hours

The Drug and Medical Technology Agency of Armenia rejected the registration of oxeladin in July 2000 since studies in Germany have shown potential carcinogenicity of the drug. (Reference: Communication to WHO, 9 August 2000.)^[2]